| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 295 | 2017 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 231 | 2018 |
| Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement A Dispenzieri, F Buadi, SK Kumar, CB Reeder, T Sher, MQ Lacy, RA Kyle, ... Mayo Clinic Proceedings 90 (8), 1054-1081, 2015 | 159 | 2015 |
| Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016 P Kapoor, SM Ansell, R Fonseca, A Chanan-Khan, RA Kyle, SK Kumar, ... JAMA oncology 3 (9), 1257-1265, 2017 | 138 | 2017 |
| Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement WI Gonsalves, FK Buadi, S Ailawadhi, PL Bergsagel, AA Chanan Khan, ... Bone marrow transplantation 54 (3), 353-367, 2019 | 124 | 2019 |
| Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study D Adams, M Polydefkis, A González-Duarte, J Wixner, AV Kristen, ... The Lancet Neurology 20 (1), 49-59, 2021 | 116 | 2021 |
| A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ... Mayo Clinic Proceedings 94 (3), 472-483, 2019 | 112 | 2019 |
| Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents N Majithia, SV Rajkumar, MQ Lacy, FK Buadi, A Dispenzieri, MA Gertz, ... Leukemia 30 (11), 2208-2213, 2016 | 109 | 2016 |
| Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia S Sidana, SV Rajkumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, ... American journal of hematology 92 (7), 668-673, 2017 | 98 | 2017 |
| Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response N Abdallah, SV Rajkumar, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, ... Blood cancer journal 10 (8), 82, 2020 | 95 | 2020 |
| Five-year survival and causes of death in patients on home parenteral nutrition for severe chronic and benign intestinal failure F Joly, J Baxter, M Staun, DG Kelly, YL Hwa, O Corcos, A De Francesco, ... Clinical nutrition 37 (4), 1415-1422, 2018 | 95 | 2018 |
| Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma M Binder, SV Rajkumar, RP Ketterling, PT Greipp, A Dispenzieri, MQ Lacy, ... Blood cancer journal 7 (9), e600-e600, 2017 | 92 | 2017 |
| Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression WI Gonsalves, SV Rajkumar, A Dispenzieri, D Dingli, MM Timm, ... Leukemia 31 (1), 130-135, 2017 | 83 | 2017 |
| Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib SK Kumar, B LaPlant, V Roy, CB Reeder, MQ Lacy, MA Gertz, K Laumann, ... Blood cancer journal 5 (8), e338-e338, 2015 | 82 | 2015 |
| Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ... Leukemia 32 (10), 2240-2249, 2018 | 78 | 2018 |
| N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma P Milani, S Vincent Rajkumar, G Merlini, S Kumar, MA Gertz, G Palladini, ... American journal of hematology 91 (11), 1129-1134, 2016 | 78 | 2016 |
| Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death R Warsame, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Blood cancer journal 5 (5), e310-e310, 2015 | 77 | 2015 |
| Natural history of t (11; 14) multiple myeloma A Lakshman, M Alhaj Moustafa, SV Rajkumar, A Dispenzieri, MA Gertz, ... Leukemia 32 (1), 131-138, 2018 | 76 | 2018 |
| Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma GP Kaufman, MA Gertz, A Dispenzieri, MQ Lacy, FK Buadi, D Dingli, ... Leukemia 30 (3), 633-639, 2016 | 72 | 2016 |
| Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities N Abdallah, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, LB Baughn, ... Blood Advances 4 (15), 3509-3519, 2020 | 69 | 2020 |
